Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333591 | 0.93 | LTA4H (0.71) | LTA4HCHRM4 | |
| SCHEMBL5310237 | 0.92 | LTA4H (0.62) | LTA4HCHRM4 | |
| SCHEMBL5657208 | 0.91 | LTA4H (0.61) | LTA4HCHRM4SIGMAR1 | |
| SCHEMBL5309936 | 0.88 | LTA4H (0.58) | LTA4HCHRM4 | |
| SCHEMBL3036812 | 0.86 | LTA4H (0.61) | LTA4HCHRM4DRD4SIGMAR1 | |
| SCHEMBL5312708 | 0.85 | LTA4H (0.54) | LTA4HCHRM4 | |
| SCHEMBL5312584 | 0.85 | LTA4H (0.54) | LTA4HSIGMAR1 | |
| SCHEMBL5310158 | 0.85 | LTA4H (0.56) | LTA4HCHRM4 | |
| SCHEMBL3039567 | 0.84 | LTA4H (0.64) | LTA4HDRD4SIGMAR1MEN1KMT2A | |
| SCHEMBL5661120 | 0.84 | LTA4H (0.55) | LTA4HDRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885CHRM4 213/4885DRD4 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.